TR199902550T2 - 5, 6, 7-Tris�bstit�e-4-aminopyrido $2,3-D] pirimidin bile�ikleri. - Google Patents
5, 6, 7-Tris�bstit�e-4-aminopyrido $2,3-D] pirimidin bile�ikleri.Info
- Publication number
- TR199902550T2 TR199902550T2 TR1999/02550T TR9902550T TR199902550T2 TR 199902550 T2 TR199902550 T2 TR 199902550T2 TR 1999/02550 T TR1999/02550 T TR 1999/02550T TR 9902550 T TR9902550 T TR 9902550T TR 199902550 T2 TR199902550 T2 TR 199902550T2
- Authority
- TR
- Turkey
- Prior art keywords
- compound
- ikleri
- bstit
- pirimidin
- aminopyrido
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Formül (II) ye sahip ve R1, R2, R3, R4 ve R5'in tanimlandigi bir bilesik, bu bilesigi tatbik etmek suretiyle adenosin kinazi inhibe etmek için bir yöntem, yukaridaki bilesigin terapötik açidan etkili bir miktari ile birlikte farmasötik olarak kabul edilebilir bir tasiyici ihtiva eden bir farmasötik terkip, tedaviye ihtiyaci olan bir memelide, beyin iskemisi, epilepsi, agri, agriya duyarlilik, enflamasyon ve sepsisi tedavi etmeye mahsus ve söz konusu memeliye, buradaki bilesigin terapötik açidan etkili bir miktarinin verilmesini içeren bir yöntem ve bu bilesikleri hazirlamak için yöntemler açiklanmistir.A compound of formula (II) and defined by R1, R2, R3, R4, and R5, a method for inhibiting adenosine kinase by administration of this compound, a pharmaceutically acceptable carrier with a therapeutically effective amount of the above compound. A pharmaceutical composition comprising a method for treating brain ischemia, epilepsy, pain, pain sensitivity, inflammation, and sepsis in a mammal in need of treatment, and comprising a therapeutically effective amount of the compound herein, and methods for preparing these compounds. it is explained.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84348497A | 1997-04-16 | 1997-04-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR199902550T2 true TR199902550T2 (en) | 2000-04-21 |
Family
ID=25290123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR1999/02550T TR199902550T2 (en) | 1997-04-16 | 1998-04-13 | 5, 6, 7-Tris�bstit�e-4-aminopyrido $2,3-D] pirimidin bile�ikleri. |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP0975633A1 (en) |
| JP (1) | JP2001520654A (en) |
| KR (1) | KR20010006462A (en) |
| CN (1) | CN1252069A (en) |
| AR (1) | AR012437A1 (en) |
| AU (1) | AU741033B2 (en) |
| BG (1) | BG103853A (en) |
| BR (1) | BR9809056A (en) |
| CA (1) | CA2286592A1 (en) |
| CO (1) | CO4940470A1 (en) |
| HU (1) | HUP0001443A3 (en) |
| IL (1) | IL131617A0 (en) |
| NO (1) | NO995035L (en) |
| NZ (1) | NZ337125A (en) |
| PL (1) | PL336265A1 (en) |
| SK (1) | SK140099A3 (en) |
| TR (1) | TR199902550T2 (en) |
| WO (1) | WO1998046604A1 (en) |
| ZA (1) | ZA983175B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001057040A1 (en) * | 2000-02-03 | 2001-08-09 | Abbott Laboratories | 6,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds |
| IL156872A0 (en) | 2001-02-12 | 2004-02-08 | Hoffmann La Roche | 6-substituted pyrido-pyrimidines |
| CN107744520A (en) * | 2017-10-25 | 2018-03-02 | 南京多宝生物科技有限公司 | Pyrimidines are preparing the application in promoting small bowel peristalsis medicine |
| CN112209924B (en) * | 2019-07-09 | 2022-04-05 | 中国科学院天津工业生物技术研究所 | Selective adenosine A1Receptor antagonists |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB774094A (en) * | 1953-01-02 | 1957-05-08 | Wellcome Found | Improvements in or relating to pyrimidine compounds |
| IL112249A (en) * | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
-
1998
- 1998-04-13 HU HU0001443A patent/HUP0001443A3/en unknown
- 1998-04-13 CA CA002286592A patent/CA2286592A1/en not_active Abandoned
- 1998-04-13 IL IL13161798A patent/IL131617A0/en unknown
- 1998-04-13 TR TR1999/02550T patent/TR199902550T2/en unknown
- 1998-04-13 EP EP98918091A patent/EP0975633A1/en not_active Withdrawn
- 1998-04-13 BR BR9809056-9A patent/BR9809056A/en not_active IP Right Cessation
- 1998-04-13 JP JP54408398A patent/JP2001520654A/en active Pending
- 1998-04-13 KR KR1019997009552A patent/KR20010006462A/en not_active Application Discontinuation
- 1998-04-13 SK SK1400-99A patent/SK140099A3/en unknown
- 1998-04-13 WO PCT/US1998/007201 patent/WO1998046604A1/en not_active Application Discontinuation
- 1998-04-13 NZ NZ337125A patent/NZ337125A/en unknown
- 1998-04-13 PL PL98336265A patent/PL336265A1/en unknown
- 1998-04-13 CN CN98804117A patent/CN1252069A/en active Pending
- 1998-04-13 AU AU71080/98A patent/AU741033B2/en not_active Ceased
- 1998-04-15 ZA ZA983175A patent/ZA983175B/en unknown
- 1998-04-15 AR ARP980101734A patent/AR012437A1/en unknown
- 1998-04-16 CO CO98020978A patent/CO4940470A1/en unknown
-
1999
- 1999-10-15 NO NO995035A patent/NO995035L/en not_active Application Discontinuation
- 1999-11-03 BG BG103853A patent/BG103853A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20010006462A (en) | 2001-01-26 |
| SK140099A3 (en) | 2000-05-16 |
| JP2001520654A (en) | 2001-10-30 |
| ZA983175B (en) | 1998-10-21 |
| AU7108098A (en) | 1998-11-11 |
| HUP0001443A2 (en) | 2000-10-28 |
| NZ337125A (en) | 2001-06-29 |
| WO1998046604A1 (en) | 1998-10-22 |
| CN1252069A (en) | 2000-05-03 |
| CA2286592A1 (en) | 1998-10-22 |
| AR012437A1 (en) | 2000-10-18 |
| HUP0001443A3 (en) | 2001-01-29 |
| NO995035D0 (en) | 1999-10-15 |
| AU741033B2 (en) | 2001-11-22 |
| BR9809056A (en) | 2000-08-01 |
| PL336265A1 (en) | 2000-06-19 |
| CO4940470A1 (en) | 2000-07-24 |
| NO995035L (en) | 1999-12-15 |
| BG103853A (en) | 2000-06-30 |
| IL131617A0 (en) | 2001-01-28 |
| EP0975633A1 (en) | 2000-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2078790A1 (en) | 3-benzylidene-1-carbamoyl-2-pyrrolidone analogues | |
| TR200102603T2 (en) | Camptothecin derivatives with antitumor activity | |
| IE781878L (en) | Imidazole derivatives | |
| CA2216796A1 (en) | Quinazoline derivatives | |
| CA2098076A1 (en) | Imidate prodrugs of pharmaceutically useful anticonvulsant sulfamates | |
| WO1996016981A3 (en) | Peptide compounds for prevention and/or treatment of no-mediated diseases | |
| NO914036D0 (en) | PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE QUINAZOLINE DERIVATIVES | |
| CA2111836A1 (en) | Spin-trapping pharmaceutical compositions and methods for use thereof | |
| CA2096841A1 (en) | Drug delivery porphyrin compositions and methods | |
| CA2140106A1 (en) | Method of treating hyperproliferative vascular disease | |
| TR199802296T2 (en) | New 2,3 disubstituted-4 (3H)-quinazolinones | |
| TR199902995T2 (en) | 9-Oxime erythromycin derivatives | |
| TR199902455T2 (en) | 5,7-Disebictie 4-Aminopyrido (2,3-D) Pyrimidine compounds and their use as adenosine kinase inhibitors | |
| TR200001140T2 (en) | 6, 11-Bridge erythromycin derivatives. | |
| TR199902550T2 (en) | 5, 6, 7-Tris�bstit�e-4-aminopyrido $2,3-D] pirimidin bile�ikleri. | |
| FI892684A (en) | Process for the preparation of therapeutically active 4-oxoimidazo [1,5-a] quinoxaline derivatives | |
| DE69122858D1 (en) | THERAPEUTIC BENZAZEPINE COMPOUNDS | |
| TR199902456T2 (en) | 6,7-ikameli-4-aminopyrido$2,3,-D]Pirimidin bile�ikleri. | |
| CA2289017A1 (en) | The use of a nitroxide or a prodrug thereof in the prophylactic and therapeutic treatment of cancer | |
| MY104829A (en) | 3-phenyl-5, 6-dihydrobenz [c]acridine-7-carboxylic acids and related compounds as cancer chemotherapeutic agents. | |
| IS4725A (en) | Derivatives of amidine and isothio urea inhibit nitric oxide synthase | |
| NO176242C (en) | Analogous Process for Preparing Therapeutically Active 5-Substituted Ornithine Derivatives | |
| DE69813886D1 (en) | NAPHTHALINE DERIVATIVES | |
| NO913644D0 (en) | PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE AMINO ACID DERIVATIVES. | |
| MX9604692A (en) | Quinoxaline derivatives for treating tinnitus. |